{
    "xml": "<topic id=\"PHP3751\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/abacavir\" basename=\"abacavir\" title=\"ABACAVIR\">\n<title>ABACAVIR</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_907\" namespace=\"/interactions/list-of-drug-interactions/antivirals/abacavir\">Abacavir</xref>\n</p>\n<data name=\"vtmid\">116084008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_149321041\" title=\"Nucleoside reverse transcriptase inhibitors\">Nucleoside reverse transcriptase inhibitors</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34645\" title=\"NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS\" namespace=\"/drug-classes/nucleoside-reverse-transcriptase-inhibitors\">NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP59720\" outputclass=\"indicationsAndDose\" rev=\"1.39\" parent=\"/drugs/abacavir\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">HIV infection in combination with other antiretroviral drugs</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>600&#8239;mg daily in 1&#8211;2 divided doses.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59879\" outputclass=\"cautions\" rev=\"1.17\" parent=\"/drugs/abacavir\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">HIV load greater than 100&#8239;000 copies/mL</ph>; <ph outputclass=\"caution\">patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59709\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/abacavir\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (abacavir).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59653\" outputclass=\"sideEffects\" rev=\"1.20\" parent=\"/drugs/abacavir\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hypersensitivity reactions</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Life-threatening hypersensitivity reactions reported&#8212;characterised by fever or rash and possibly nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis; laboratory abnormalities may include raised liver function tests and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time.</p>\n<p>Discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out, even when other diagnoses possible&#8212;if rechallenge necessary it must be carried out in hospital setting; if abacavir is stopped for any reason other than hypersensitivity, exclude hypersensitivity reaction as the cause and rechallenge only if medical assistance is readily available; care needed with concomitant use of drugs which cause skin toxicity.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Gastro-intestinal disturbances</p>\n<p>More common in children.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Rash</p>\n<p>More common in children.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59923\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.19\" parent=\"/drugs/abacavir\">\n<title>Allergy and cross-sensitivity</title>\n<body>\n<section outputclass=\"allergyAndCrossSensitivityCrossSensitivity\">\n<sectiondiv>\n<p>Caution&#8212;increased risk of hypersensitivity reaction in presence of HLA-B*5701 allele.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59800\" outputclass=\"hepaticImpairment\" parent=\"/drugs/abacavir\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Monitor closely in mild impairment (combination preparations not recommended as reduced abacavir dose may be required).</p>\n<p>Avoid in moderate impairment unless essential&#8212;close monitoring recommended.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59679\" outputclass=\"renalImpairment\" parent=\"/drugs/abacavir\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid in end-stage renal disease.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59671\" outputclass=\"preTreatmentScreening\" rev=\"1.7\" parent=\"/drugs/abacavir\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p>Test for HLA-B*5701 allele before treatment or if restarting treatment and HLA-B*5701 status not known.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59615\" outputclass=\"monitoringRequirements\" parent=\"/drugs/abacavir\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor for symptoms of hypersensitivity reaction every 2 weeks for 2 months.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58557\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.10\" parent=\"/drugs/abacavir\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Flavours of oral liquid formulations may include banana, or strawberry.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59690\" outputclass=\"patientAndCarerAdvice\" rev=\"1.13\" parent=\"/drugs/abacavir\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>Patients should be provided with an Alert Card and advised to keep it with them at all times.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients and their carers should be told the importance of regular dosing (intermittent therapy may increase the risk of sensitisation), how to recognise signs of hypersensitivity, and advised to seek immediate medical attention if symptoms develop or before re-starting treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3751-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/abacavir\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77160\" title=\"Tablet\" namespace=\"/drugs/abacavir/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77153\" title=\"Oral solution\" namespace=\"/drugs/abacavir/oral-solution\">Oral solution</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP106633\" namespace=\"/drugs/abacavir-with-dolutegravir-and-lamivudine\" title=\"ABACAVIR WITH DOLUTEGRAVIR AND LAMIVUDINE\" count=\"1\" rel=\"backlink\">ABACAVIR WITH DOLUTEGRAVIR AND LAMIVUDINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85564\" namespace=\"/drugs/abacavir-with-lamivudine\" title=\"ABACAVIR WITH LAMIVUDINE\" count=\"1\" rel=\"backlink\">ABACAVIR WITH LAMIVUDINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85565\" namespace=\"/drugs/abacavir-with-lamivudine-and-zidovudine\" title=\"ABACAVIR WITH LAMIVUDINE AND ZIDOVUDINE\" count=\"1\" rel=\"backlink\">ABACAVIR WITH LAMIVUDINE AND ZIDOVUDINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78275\" namespace=\"/treatment-summaries/hiv-infection\" title=\"HIV infection\" count=\"2\" rel=\"backlink\">HIV infection</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_907\" namespace=\"/interactions/list-of-drug-interactions/antivirals/abacavir\" title=\"Abacavir\" count=\"1\" rel=\"link\">Abacavir</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34645\" namespace=\"/drug-classes/nucleoside-reverse-transcriptase-inhibitors\" title=\"NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS\" count=\"1\" rel=\"link\">NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77160\" namespace=\"/drugs/abacavir/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77153\" namespace=\"/drugs/abacavir/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n</links>\n</topic>",
    "id": "PHP3751",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/abacavir",
    "basename": "abacavir",
    "title": "ABACAVIR",
    "interactants": [
        {
            "id": "bnf_int_907",
            "label": "Abacavir"
        }
    ],
    "vtmid": "116084008",
    "drugClassification": [
        "Nucleoside reverse transcriptase inhibitors"
    ],
    "inheritsFromClass": [
        "NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "HIV infection in combination with other antiretroviral drugs",
                        "html": "HIV infection in combination with other antiretroviral drugs"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "600 mg daily in 1&#8211;2 divided doses.",
                        "html": "<p>600&#8239;mg daily in 1&#8211;2 divided doses.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "HIV load greater than 100 000 copies/mL",
                "html": "HIV load greater than 100&#8239;000 copies/mL"
            },
            {
                "type": "cautions",
                "textContent": "patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%)",
                "html": "patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (abacavir).",
                "html": "<p>Appendix 1 (abacavir).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hypersensitivity reactions",
                        "html": "Hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Hypersensitivity reactions",
                "textContent": "Life-threatening hypersensitivity reactions reported&#8212;characterised by fever or rash and possibly nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis; laboratory abnormalities may include raised liver function tests and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time.\n\nDiscontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out, even when other diagnoses possible&#8212;if rechallenge necessary it must be carried out in hospital setting; if abacavir is stopped for any reason other than hypersensitivity, exclude hypersensitivity reaction as the cause and rechallenge only if medical assistance is readily available; care needed with concomitant use of drugs which cause skin toxicity.",
                "html": "<p>Life-threatening hypersensitivity reactions reported&#8212;characterised by fever or rash and possibly nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis; laboratory abnormalities may include raised liver function tests and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time.</p><p>Discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out, even when other diagnoses possible&#8212;if rechallenge necessary it must be carried out in hospital setting; if abacavir is stopped for any reason other than hypersensitivity, exclude hypersensitivity reaction as the cause and rechallenge only if medical assistance is readily available; care needed with concomitant use of drugs which cause skin toxicity.</p>"
            },
            {
                "type": "advice",
                "title": "Gastro-intestinal disturbances",
                "textContent": "More common in children.",
                "html": "<p>More common in children.</p>"
            },
            {
                "type": "advice",
                "title": "Rash",
                "textContent": "More common in children.",
                "html": "<p>More common in children.</p>"
            }
        ]
    },
    "allergyAndCrossSensitivity": {
        "crossSensitivity": [
            {
                "type": "crossSensitivity",
                "textContent": "Caution&#8212;increased risk of hypersensitivity reaction in presence of HLA-B*5701 allele.",
                "html": "<p>Caution&#8212;increased risk of hypersensitivity reaction in presence of HLA-B*5701 allele.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Monitor closely in mild impairment (combination preparations not recommended as reduced abacavir dose may be required).\n\nAvoid in moderate impairment unless essential&#8212;close monitoring recommended.\n\nAvoid in severe impairment.",
                "html": "<p>Monitor closely in mild impairment (combination preparations not recommended as reduced abacavir dose may be required).</p><p>Avoid in moderate impairment unless essential&#8212;close monitoring recommended.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid in end-stage renal disease.",
                "html": "<p>Manufacturer advises avoid in end-stage renal disease.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "textContent": "Test for HLA-B*5701 allele before treatment or if restarting treatment and HLA-B*5701 status not known.",
                "html": "<p>Test for HLA-B*5701 allele before treatment or if restarting treatment and HLA-B*5701 status not known.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor for symptoms of hypersensitivity reaction every 2 weeks for 2 months.",
                "html": "<p>Monitor for symptoms of hypersensitivity reaction every 2 weeks for 2 months.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Flavours of oral liquid formulations may include banana, or strawberry.",
                "html": "<p>Flavours of oral liquid formulations may include banana, or strawberry.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "Patients should be provided with an Alert Card and advised to keep it with them at all times.",
                "html": "<p>Patients should be provided with an Alert Card and advised to keep it with them at all times.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients and their carers should be told the importance of regular dosing (intermittent therapy may increase the risk of sensitisation), how to recognise signs of hypersensitivity, and advised to seek immediate medical attention if symptoms develop or before re-starting treatment.",
                "html": "<p>Patients and their carers should be told the importance of regular dosing (intermittent therapy may increase the risk of sensitisation), how to recognise signs of hypersensitivity, and advised to seek immediate medical attention if symptoms develop or before re-starting treatment.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77160",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77153",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP106633",
                "label": "ABACAVIR WITH DOLUTEGRAVIR AND LAMIVUDINE",
                "type": "drug"
            },
            {
                "id": "PHP85564",
                "label": "ABACAVIR WITH LAMIVUDINE",
                "type": "drug"
            },
            {
                "id": "PHP85565",
                "label": "ABACAVIR WITH LAMIVUDINE AND ZIDOVUDINE",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78275",
                "label": "HIV infection",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_907",
                "label": "Abacavir",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34645",
                "label": "NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77160",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77153",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    }
}